WALTHAM,
Mass., Dec. 14, 2023 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a
clinical-stage biopharmaceutical company developing an innovative
pipeline of cancer therapies, today announced the pricing of an
underwritten public offering of 10,810,810 shares of its common
stock. The public offering price of each share of common stock is
$18.50. The aggregate gross proceeds
from this offering are expected to be approximately $200.0 million, before deducting underwriting
discounts and commissions and other offering expenses payable by
Syndax. In addition, Syndax granted the underwriters a 30-day
option to purchase up to an additional 1,621,621 shares of common
stock. All of the shares of common stock are being sold by Syndax.
The offering is expected to close on December 19, 2023, subject to customary closing
conditions.
Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen and Stifel
are acting as joint book-running managers for the offering. B.
Riley Securities is acting as manager for the offering.
The shares are being offered pursuant to an automatically
effective "shelf" registration statement previously filed with the
Securities and Exchange Commission ("SEC"). A preliminary
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available on the
website of the SEC at www.sec.gov. A final prospectus supplement
and accompanying prospectus relating to the offering will be filed
with the SEC. When available, copies of the final prospectus
supplement and accompanying prospectus relating to the offering may
be obtained from: Goldman Sachs and Co. LLC, Attention: Prospectus
Department, 200 West Street, New York,
NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316
or by emailing Prospectus-ny@ny.email.gs.com; J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717,
telephone: (866) 803-9204, or by emailing
prospectuseq_fi@jpmchase.com; or Cowen and Company, LLC, 599
Lexington Avenue, New York, NY
10022, by emailing Prospectus_ECM@cowen.com or by telephone at
(833) 297-2926; or Stifel, Nicolaus & Company, Incorporated,
Attention: Prospectus Department, One
Montgomery Street, Suite 3700, San
Francisco, California 94104, by telephone at (415) 364-2720
or by emailing syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus, which are a part
of the effective registration statement.
About Syndax
Syndax Pharmaceuticals is a clinical
stage biopharmaceutical company developing an innovative pipeline
of cancer therapies. Highlights of the Company's pipeline include
revumenib, a highly selective inhibitor of the menin–KMT2A binding
interaction, and axatilimab, a monoclonal antibody that blocks the
colony stimulating factor 1 (CSF-1) receptor.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the
proposed public offering. There can be no assurance that Syndax
will be able to complete the proposed public offering on the
anticipated terms, or at all. Other factors that may cause Syndax's
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Syndax's filings with the SEC, including the "Risk Factors"
sections contained therein, as well as the risks identified in the
registration statement and the preliminary prospectus supplement
relating to the offering. These forward-looking statements are
based on Syndax's expectations and assumptions as of the date of
this press release. Except as required by law, Syndax assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Syndax Contact
Sharon
Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-pricing-of-200-million-public-offering-of-common-stock-302016293.html
SOURCE Syndax Pharmaceuticals, Inc.